The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Cantwell, B M
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid). [electronic resource] - British journal of cancer Aug 1988 - 189-90 p. digital
Publication Type: Journal Article
0007-0920
10.1038/bjc.1988.190 doi
Adenocarcinoma--drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Colonic Neoplasms--drug therapy
Fluorouracil--therapeutic use
Folic Acid--analogs & derivatives
Humans
Middle Aged
Quinazolines--therapeutic use
Rectal Neoplasms--drug therapy
Thymidylate Synthase--antagonists & inhibitors
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid). [electronic resource] - British journal of cancer Aug 1988 - 189-90 p. digital
Publication Type: Journal Article
0007-0920
10.1038/bjc.1988.190 doi
Adenocarcinoma--drug therapy
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Colonic Neoplasms--drug therapy
Fluorouracil--therapeutic use
Folic Acid--analogs & derivatives
Humans
Middle Aged
Quinazolines--therapeutic use
Rectal Neoplasms--drug therapy
Thymidylate Synthase--antagonists & inhibitors